The results showed that the contents of AST, ALT, and γ-GT were significantly increased in NAFLD rats compared with that in control rats, and the relative indexes were reversed by middle dose or high dose of SSJZF treatment, suggesting SSJZF diminished hepatic function damage in rats with NAFLD. The gene discussed is GOT1; the disease is metabolic dysfunction-associated steatotic liver disease.